Guardant Health
Guardant Health, Inc., a leading precision oncology company, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2012, the company has rapidly established itself in the biotechnology industry, focusing on non-invasive cancer detection and monitoring through advanced genomic testing. Guardant Health is renowned for its flagship product, the Guardant360® test, which provides comprehensive genomic profiling of solid tumours using a simple blood draw. This innovative approach allows for personalised treatment strategies, setting the company apart in the competitive landscape of cancer diagnostics. With a strong market position, Guardant Health has achieved notable milestones, including partnerships with major pharmaceutical companies and contributions to pivotal clinical trials. Its commitment to transforming cancer care through cutting-edge technology continues to drive its success in the oncology sector.
DitchCarbon Score
How does Guardant Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Guardant Health's score of 24 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Guardant Health's reported carbon emissions
Guardant Health, headquartered in the United States, has not publicly disclosed specific carbon emissions data for the most recent year. However, the company is committed to reducing its carbon footprint and has established near-term reduction targets. As of November 2023, Guardant Health is classified as "Committed" to these targets, indicating a proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector. While no absolute emissions figures are available, the absence of a net-zero commitment suggests that Guardant Health is still in the early stages of formalising its long-term climate strategy. The company has not specified a net-zero year or long-term reduction targets, but its commitment to near-term targets reflects an intention to align with industry standards for climate action. In summary, Guardant Health is actively working towards reducing its carbon emissions, although specific data and long-term goals are yet to be disclosed. The company's commitment to near-term targets positions it as a participant in the broader movement towards sustainability in the life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Guardant Health is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
